At the news
? MIXEDIMPACT 7/10 8-K filed Feb 26, 2026 at 07:30 ET
Vera Therapeutics reported strong business progress with positive Phase 3 data for atacicept in IgA nephropathy, FDA priority review granted with a PDUFA date of July 7, 2026, and a robust balance sheet from $800 million in financings. However, the company reported a significant net loss increase to $299.6 million in 2025 from $152.1 million in 2024, driven by higher R&D and G&A expenses.
- Positive Phase 3 data from the ORIGIN 3 study of atacicept in IgA nephropathy presented at ASN Kidney Week and published in NEJM
- FDA granted priority review to the Biologics License Application (BLA) for atacicept with a PDUFA date of July 7, 2026
- Equity and debt financings in 2025 raised $800 million in gross proceeds, strengthening the balance sheet
- Cash, cash equivalents, and marketable securities totaled $714.6 million as of December 31, 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access